United Therapeutics price to free cash flow UTHR

Market value divided by free cash flow over the last twelve months, since 2011.

Today, Oct 23, 2026: 23.1×
10-year median: 14.3×
Against its 10-year history: 98th; percentile: 0 is its lowest day, 100 its highest
10-year range: 7.4× to 24.8×
Peer median: 27.2×

United Therapeutics' price to free cash flow is 23.1× as of Oct 23, 2026.

That is above its ten-year median of 14.3×, higher than on 98% of days in the last ten years.

Over that time it ranged from 7.4× in Apr 2019 to 24.8× in Apr 2026.

The median for 10 biotech stocks of a similar size is 27.2×.

Price to free cash flow over time

median 14.3×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	23.1×	17.8×	24.8×
2025	19.5×	11.3×	19.8×
2024	17.9×	13.1×	20.4×
2023	13.5×	13.5×	18.5×
2022	18.7×	12.3×	19.8×
2021	20.0×	10.2×	20.0×
2020	10.2×	7.5×	10.2×
2019	7.7×	7.4×	12.6×
2018	11.1×	8.6×	13.3×
2017	9.8×	7.7×	15.8×
2016	13.5×	10.7×	17.4×
2015	16.7×	13.2×	28.3×
2014	20.2×	10.8×	26.1×
2013	14.8×	10.0×	16.3×
2012	14.7×	10.4×	19.1×
2011	14.1×	9.4×	18.4×

Against its peers

Companies in Biotechnology nearest United Therapeutics' size, closest first, today.

Company	Price to free cash flow
UTHRUnited Therapeutics	23.1×
INCYIncyte	12.2×
ALNYAlnylam Pharmaceuticals	37.8×
EXELExelixis	13.6×
ONCBeOne Medicines	32.3×
NBIXNeurocrine Biosciences	16.7×
HALOHalozyme Therapeutics	17.7×
TECHBIO-TECHNE	43.2×
RGENRepligen	89.2×
KRYSKrystal Biotech	35.8×
REGNRegeneron Pharmaceuticals	22.0×
Peer median	27.2×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on United Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.